Robotic pill maker Rani pauses programs, cuts headcount to extend cash runway through 2025
Rani Therapeutics is suspending two programs and axing a third program alongside a quarter of its workforce as part of a strategic reshuffling so that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
